EGFR and non-small cell lung carcinoma: We investigated whether EGFR expression levels could predict for response to gefitinib in patients with advanced non-small-cell lung cancer (NSCLC), who received gefitinib (250 mg day−1) as part of a worldwide compassionate-use programme.